> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# AZ Wants EUA for Covid Prophylaxis Drug
- URL: https://www.fdaweb.com/az-wants-eua-for-covid-prophylaxis-drug/
- Published: 2021-10-05T12:00:00.000Z
- Updated: 2026-09-14T17:17:48.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5150299

AstraZeneca is asking FDA for an emergency use authorization (EUA) for its AZD7442 long-acting antibody (LAAB) combination for prophylaxis of symptomatic Covid-19\. The company [says](https://www.astrazeneca.com/media-centre/press-releases/2021/azd7442-request-for-emergency-use-authorization-for-covid-19-prophylaxis-filed-in-us.html?ref=fdaweb.com) that if FDA approves the EUA, it would be the first LAAB to receive an EUA for Covid-19 prevention.

The AZ statement says the filing includes data from the PROVENT Phase 3 trial showing a 77% reduction in risk of developing symptomatic Covid-19 with the LAAB combination. The filing also includes data from the STORM CHASER Phase 3 and Phase 1 trials, it says.

The company says AZD7442 is a combination of tixagevimab and cilgavimab derived from B-cells donated by convalescent patients after the SARS-CoV-2 virus. It was discovered by Vanderbilt University Medical Center and licensed to AZ.